Canada Pharmaceuticals & Healthcare Q1 2019
The provision in the United States-Mexico-Canada Agreement extending biologic data protection from eight to ten yearswill increase the cost of medicines in Canada and weigh negatively on the biosimilar industry. This poses upside risks to our marketforecasts, given the increasing impact that biologics are having on pharmaceutical spending. Rising pharmaceutical and healthcarespending combined with the eventual introduction of a universal, single-payer pharmacare system will ensure that pricing pressureand cost control measures remain a government priority.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook